No new drug, just data: large european study to map myelofibrosis outcomes
NCT ID NCT06533813
First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 3 times
Summary
This is an observational study that will follow about 617 people with myelofibrosis across Europe. Researchers will collect information from medical records to see how the disease progresses and how patients respond to standard treatments. No experimental drug or intervention is being tested. The goal is to better understand the disease and improve future care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette- S.C. Ematologia U
NOT_YET_RECRUITINGTorino, 10126, Italy
-
A.S.O. SS. Antonio e Biagio e C.Arrigo, SC Ematologia
RECRUITINGAlessandria, 15121, Italy
-
AOU Careggi di Firenze, Divisione di Ematologia
RECRUITINGFlorence, Italy
-
ASST Grande Ospedale Metropolitano Niguarda, Divisione di Ematologia
RECRUITINGMilan, Italy
-
ASST Papa Giovanni XXIII, SC Ematologia
RECRUITINGBergamo, Italy
-
Azienda Ospedaliera Universitaria Federico II, Divisione di Ematologia
RECRUITINGNaples, Italy
-
Azienda Ospedaliera Universitaria Integrata - Ospedale Borgo Roma, Unità di Ematologia
RECRUITINGVerona, Italy
-
Azienda Ospedaliero - Universitaria "Policlinico Vittorio Emanuele" - PO Gaspare Rodolico, Dipartimento di ematologia con Trapianto di midollo Osseo
RECRUITINGCatania, Italy
-
Azienda Ospedaliero Universitaria Maggiore della Carità, SCDU Ematologia
RECRUITINGNovara, Italy
-
Azienda ULSS 8 Berica - Ospedale San Bortolo, Divisione di Ematologia
RECRUITINGVicenza, Italy
-
Department and Clinic of Haematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University
RECRUITINGWroclaw, Poland
-
Department of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute
RECRUITINGBucharest, Romania
-
Department of Hematology, University Hospital, Jagiellonian University Medical College
RECRUITINGKrakow, Poland
-
Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Ematologia
RECRUITINGMilan, Italy
-
Fondazione IRCCS Policlinico San Matteo, Divisione di Ematologia
RECRUITINGPavia, Italy
-
Fondazione IRCCS San Gerardo dei Tintori
RECRUITINGMonza, Italy
-
Fondazione Policlinico Universitario A. Gemelli - Università Cattolica del Sacro Cuore, UCSC Ematologia
RECRUITINGRoma, Italy
-
Hematology Center after Prof.R.H. Yeolyan
RECRUITINGYerevan, Armenia
-
Hematology and Hemotherapy Department, 12 de Octubre University Hospital
RECRUITINGMadrid, Spain
-
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) - Hospital Clinic
RECRUITINGBarcelona, Spain
-
Ospedale Cardinale G. Panico
NOT_YET_RECRUITINGTricase, Italy
-
Ospedale San Raffaele, Unità Operativa di Ematologia e Trapianto Midollo Osseo
RECRUITINGMilan, Italy
-
Policlinico S. Orsola - Malpighi, Unità di Ematologia
RECRUITINGBologna, Italy
-
Policlinico Umberto I, Dipartimento Ematologia, Oncologia e Dermatologia
RECRUITINGRoma, Italy
-
University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care Johannes Wesling Medical Center Minden UKRUB, University of Bochum
RECRUITINGMinden, Germany
-
University Hospital Halle Department of Hematology/Oncology
NOT_YET_RECRUITINGHalle, Germany
-
University Medicine Hannover
RECRUITINGHanover, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new daily pill shrink the spleen and ease myelofibrosis symptoms?
- Can a new pill tame myelofibrosis?
- MRI as a window into bone marrow disease: a new biomarker test?
- Can a menin inhibitor tame myelofibrosis when standard drugs fall short?
- Can a drug free myelofibrosis patients from frequent blood transfusions?
- Heart safety check for new myelofibrosis drug in healthy volunteers